Clinical Investigation of Proton Treatment in Hodgkin Lymphoma Patients - PRO-Hodgkin

Hodgkin Lymphoma patients with limited stage are commonly cured with limited chemotherapy followed by radiotherapy. Studies have shown a risk of late toxicity from the radiotherapy, such as second cancer, heart failure and lung toxicity. With proton therapy the dose to normal tissue can be minimised without compromising the dose to the tumor. The aim of our study is to investigate whether proton therapy can be delivered in a safe way to Hodgkin Lymphoma patients with less late side effects than conventional radiotherapy, while retaining the high cure rate. This is a multicentre phase II study

Trial Details

NCT ID
NCT06883604
Phase
NA
Sponsor
Uppsala University Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Proton therapy.
Locations (sample)
  • Gothenburg, Sweden|57.70716,11.96679
  • Lund, Sweden|55.70584,13.19321
  • Örebro, Sweden|59.27412,15.2066
  • Solna, Sweden|59.36004,18.00086
  • Umeå, Sweden|63.82842,20.25972

Key Eligibility Criteria

  • Histological diagnosis of classic Hodgkin Lymphoma.
  • Ann Arbour stage 1A, 1B or 2A.
  • Both patients with and without risk factors, i.e. bulky disease, erythrocyte sedimentation rate (ESR)\>50, more than two involved sites.
  • Supra diaphragmal disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →